Zhenqing Feng

872 total citations
26 papers, 674 citations indexed

About

Zhenqing Feng is a scholar working on Oncology, Molecular Biology and Parasitology. According to data from OpenAlex, Zhenqing Feng has authored 26 papers receiving a total of 674 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Parasitology. Recurrent topics in Zhenqing Feng's work include CAR-T cell therapy research (7 papers), Parasites and Host Interactions (6 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Zhenqing Feng is often cited by papers focused on CAR-T cell therapy research (7 papers), Parasites and Host Interactions (6 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Zhenqing Feng collaborates with scholars based in China, United States and Canada. Zhenqing Feng's co-authors include Qi Tang, Lizhou Jia, Jin Zhu, Lisha Qi, Na Niu, Krishna Vanaja Donkena, Weiwei Shen, Jing Zhang, Junsong Chen and Jinsong Liu and has published in prestigious journals such as Nature Communications, PLoS ONE and Biochemical and Biophysical Research Communications.

In The Last Decade

Zhenqing Feng

24 papers receiving 664 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhenqing Feng China 14 368 261 204 150 84 26 674
Katsuyoshi Furumoto Japan 11 290 0.8× 267 1.0× 414 2.0× 102 0.7× 69 0.8× 24 755
Ingrid Ljuslinder Sweden 17 376 1.0× 402 1.5× 167 0.8× 123 0.8× 41 0.5× 40 800
Lourdes Farré Brazil 18 335 0.9× 328 1.3× 527 2.6× 159 1.1× 53 0.6× 54 1.2k
Rena Morita Japan 15 577 1.6× 429 1.6× 303 1.5× 178 1.2× 36 0.4× 36 943
Jan Martínek United States 7 397 1.1× 244 0.9× 492 2.4× 75 0.5× 117 1.4× 14 924
Nahoko Suzuki Japan 8 393 1.1× 382 1.5× 505 2.5× 93 0.6× 124 1.5× 11 1.1k
Catherine Alcaïde‐Loridan France 18 257 0.7× 360 1.4× 408 2.0× 78 0.5× 70 0.8× 31 880
Anna Merlo Italy 17 384 1.0× 332 1.3× 254 1.2× 115 0.8× 90 1.1× 32 825
Han‐Ik Bae South Korea 12 296 0.8× 510 2.0× 98 0.5× 232 1.5× 52 0.6× 38 836
Ding Ma China 17 198 0.5× 557 2.1× 151 0.7× 166 1.1× 153 1.8× 33 915

Countries citing papers authored by Zhenqing Feng

Since Specialization
Citations

This map shows the geographic impact of Zhenqing Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenqing Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenqing Feng more than expected).

Fields of papers citing papers by Zhenqing Feng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenqing Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenqing Feng. The network helps show where Zhenqing Feng may publish in the future.

Co-authorship network of co-authors of Zhenqing Feng

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenqing Feng. A scholar is included among the top collaborators of Zhenqing Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenqing Feng. Zhenqing Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peng, Yan, Wenqing Zhang, Yufeng Chen, et al.. (2023). Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma. Pharmacological Research. 188. 106656–106656. 35 indexed citations
2.
Guo, Jiaojiao, Jingjing Wang, Lizhou Jia, et al.. (2021). Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. Frontiers in Oncology. 11. 546586–546586. 53 indexed citations
3.
Yu, Zhuang, Junxia Liu, Zhenqing Feng, et al.. (2021). Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells. Molecular Therapy — Nucleic Acids. 23. 1053–1065. 35 indexed citations
4.
Zhou, Shujuan, Jia Wei, Naiqing Ding, et al.. (2021). Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells. OncoTargets and Therapy. Volume 14. 835–844. 6 indexed citations
5.
Ji, Lei, Lili Zhang, Xiu‐Mei Zhang, et al.. (2021). Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway. Digestive Diseases and Sciences. 67(3). 880–891. 9 indexed citations
6.
Wang, Huiping, Jiakui Zhang, Qianshan Tao, et al.. (2020). Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia. Nature Communications. 11(1). 5928–5928. 48 indexed citations
7.
Zhou, Yan, Hongmei Yong, Xudong Wang, et al.. (2019). Elevated epiregulin expression predicts poor prognosis in gastric cancer. Pathology - Research and Practice. 215(5). 873–879. 16 indexed citations
8.
Chen, Junsong, Na Niu, Jing Zhang, et al.. (2019). Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer. Current Cancer Drug Targets. 19(5). 360–367. 116 indexed citations
9.
Mao, Yuan, Weifei Fan, Hao Hu, et al.. (2019). MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. Journal of Hematology & Oncology. 12(1). 106–106. 47 indexed citations
10.
Tang, Xiaojun, Qi Tang, Yuan Mao, et al.. (2019). <p>CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo</p>. OncoTargets and Therapy. Volume 12. 9341–9350. 25 indexed citations
11.
Zhao, Wei, Qi Tang, Xiaochen Huang, et al.. (2017). Trop2 as an oncogene in gastric cancer by regulating PI3K/Akt signaling pathway. 1(2). 21–29.
12.
Cao, Qing, Dawei Zhang, Yuan Mao, et al.. (2016). A human Fab exclusively binding to the extracellular domain of LMP2A. Biochemical and Biophysical Research Communications. 482(2). 226–231. 1 indexed citations
13.
Li, Hong, Zhenqing Feng, Tom C. Tsang, et al.. (2014). Fusion of HepG2 cells with mesenchymal stem cells increases cancer-associated and malignant properties: An in vivo metastasis model. Oncology Reports. 32(2). 539–547. 41 indexed citations
14.
Chen, Ximin, Guipeng Ding, Jian Sun, et al.. (2013). A Human Anti-c-Met Fab Fragment Conjugated with Doxorubicin as Targeted Chemotherapy for Hepatocellular Carcinoma. PLoS ONE. 8(5). e63093–e63093. 38 indexed citations
15.
Wang, Xin, Aixia Zhang, Yu Liu, et al.. (2012). Anti-Idiotypic Antibody Specific to GAD65 Autoantibody Prevents Type 1 Diabetes in the NOD Mouse. PLoS ONE. 7(2). e32515–e32515. 12 indexed citations
16.
Lei, Jiahui, et al.. (2011). Evaluation of an IgY-Based Immunomagnetic Enzyme-Linked Immunosorbent Assay System for Detection of Circulating Schistosoma japonicum Antigen in Serum Samples from Patients in China. American Journal of Tropical Medicine and Hygiene. 85(6). 1054–1059. 18 indexed citations
17.
Jia, Xiaoqin, et al.. (2011). Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo.. PubMed. 124(22). 3794–9. 16 indexed citations
18.
Feng, Zhenqing, et al.. (2004). Nanoparticles as a vaccine adjuvant of anti-idiotypic antibody against schistosomiasis.. PubMed. 117(1). 83–7. 10 indexed citations
19.
Song, Xiao‐Tong, et al.. (2002). [Construction and expression of single chain Fv gene of anti-idiotypic monoclonal antibody NP30 of Schistosoma japonicum].. PubMed. 20(3). 152–4. 1 indexed citations
20.
Feng, Zhenqing, et al.. (2002). Protective immunity induced by the anti-idiotypic monoclonal antibody NP30 of Schistosoma japonicum.. PubMed. 115(4). 576–9. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katsuyoshi Furumoto Breakdown of academic impact, for papers by Ingrid Ljuslinder Breakdown of academic impact, for papers by Lourdes Farré Breakdown of academic impact, for papers by Rena Morita Breakdown of academic impact, for papers by Jan Martínek Breakdown of academic impact, for papers by Nahoko Suzuki Breakdown of academic impact, for papers by Catherine Alcaïde‐Loridan Breakdown of academic impact, for papers by Anna Merlo Breakdown of academic impact, for papers by Han‐Ik Bae Breakdown of academic impact, for papers by Ding Ma
Rankless by CCL
2026